Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06145412 · ClinicalTrials.gov registry record · Phase 2
A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 7
- Study locations
NCT06145412: Active Phase 2 study of Head and Neck Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06145412 is a Phase 2 study of Head and Neck Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 4 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06145412, a Phase 2 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test whether treatment with Xevinapant added to standard chemoradiation after surgery is an effective treatment for people with high-risk head and neck cancers.
Primary Outcome
Progression free survival will be defined as the time from the start of treatment to biopsyproven locoregional recurrence, distant tumor recurrence, or death. For patients without evidence of gross disease at registration, any locoregional progression will be considered a PFS event. For patients with gross disease at registration, progression-free survival will be determined based upon RECIST 1.1 criteria.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Xevinapan
- RADIATION External beam
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What the registry record for NCT06145412 still lists
NCT06145412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT06145412 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06145412 about?
NCT06145412 is a clinical study titled "A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer". The purpose of this study is to test whether treatment with Xevinapant added to standard chemoradiation after surgery is an effective treatment for people with high-risk head and neck cancers.
What is the current status of trial NCT06145412?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2023-11-16. Estimated completion is 2026-11.
What conditions does trial NCT06145412 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT06145412?
The interventions under investigation include: Cisplatin (DRUG), Xevinapan (DRUG), External beam (RADIATION).
Who is sponsoring clinical trial NCT06145412?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06145412 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06145412's enrollment target sits among peer trials
4 246th of 250 higher than 5 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI